Skip to content

Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer

Prostate Metastases

This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.

null

Conditions de participation

  • Sexe:

    MALE

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Histologically-proven metastatic prostate cancer
* Presence of low-volume or high-volume metastases (high volume defined as the presence of visceral metastases or ≥4 bone lesions with at least 1 lesion beyond the vertebral bodies and pelvis.)
* Planned to or receiving systemic treatment ADT +/- ARAT as per physician discretion (Previous chemotherapy allowed if completed more than 6 weeks prior to randomization.)
* Planned for EBRT
* ECOG 0 or 1
* Age 18 years or older

Exclusion Criteria:

* Prior radiotherapy to pelvis
* Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
* Any condition where radiotherapy is contraindicated

Lieu de l'étude

University Health Network, Princess Margaret Hospital
University Health Network, Princess Margaret Hospital
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Peter Chung, MD

[email protected]
416-946-4501
Étude parrainée par
University Health Network, Toronto
Participants recherchés
Plus d'informations
ID de l'étude: NCT05656794